Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110584 | 0.90 | IRAK4 (0.33) | IRAK4JAK1 | |
| SCHEMBL5949637 | 0.89 | CHRM2 (0.39) | — | |
| SCHEMBL2093735 | 0.86 | — | — | |
| SCHEMBL1678728 | 0.81 | — | — | |
| SCHEMBL5868679 | 0.81 | GNAI3 (0.38) | — | |
| SCHEMBL500360 | 0.76 | — | — | |
| SCHEMBL5949532 | 0.76 | CHRM2 (0.37) | — | |
| SCHEMBL1678693 | 0.76 | KDM4E (0.42) | JAK1 | |
| SCHEMBL1679234 | 0.76 | — | — | |
| SCHEMBL1356264 | 0.74 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | claimed |
| EP-0791592-B1 | Azetidines | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | claimed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | claimed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | claimed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| EP-0791592-B1 | Azetidines | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| EP-0871623-B1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER RES & DEV (IE) | 2003-02-12 | — | — | EP | disclosed |
| US-6242438-B1 | 3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists | PFIZER INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-0871623-A1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | disclosed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997025322-A1 | 3-AZETIDINYLALKYLPIPERIDINES OR -PYRROLIDINES AS TACHYKININ ANTAGONISTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-17 | — | — | WO | disclosed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | IRAK4 1041/4885TDP1 2749/4885JAK1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.